Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jun;42(6):1503-5.
doi: 10.1128/AAC.42.6.1503.

Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms

Affiliations

Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms

G A Pankuch et al. Antimicrob Agents Chemother. 1998 Jun.

Abstract

Trovafloxacin pneumococcal and staphylococcal postantibiotic effects (PAEs) were 0.7 to 1.8 and 0.7 to 2.4 h, respectively. For Escherichia coli and Pseudomonas aeruginosa, PAEs were 2.4 to 4.4 h. Pneumococcal and staphylococcal postantibiotic sub-MIC effects (PA-SMEs) (0.4 times the MIC) were 2.3 to 3.7 and 2.4 to > 9.2 h, respectively, and E. coli PA-SMEs (0.3 times the MIC) were 6.8 to > 12.0 h. For one P. aeruginosa strain, the PA-SME (0.4 times the MIC) was > 10 h; in the other, rapid bactericidal activity precluded measurement.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Boswell F J, Andrews J M, Wise R. Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa. J Antimicrob Chemother. 1997;39:811–814. - PubMed
    1. Cars O, Odenholt-Tornqvist I. The postantibiotic subMIC effect in vitro and in vivo. J Antimicrob Chemother. 1993;31:159–166. - PubMed
    1. Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):6–8. - PubMed
    1. Craig W A, Gudmundsson S. Postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, Md: The Williams & Wilkins Co.; 1996. pp. 296–329.
    1. Eliopoulos G M, Klimm K, Eliopoulos C T, Ferraro M J, Moellering R C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. J Antimicrob Chemother. 1993;37:366–370. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources